- Home
- CMMB vs TULP Comparison
CMMB vs TULP Comparison
Compare CMMB & TULP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.57
N/A
Current Price
$4.05
Company Overview
Basic Information| Metric | CMMB | TULP |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 8.5M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMMB | TULP |
|---|---|---|
| Price | $1.57 | $4.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $26.50 | N/A |
| AVG Volume (30 Days) | ★ 57.9K | 13.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.75 | ★ $3.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $3.73 |
| 52 Week High | $3.86 | $4.79 |
Technical Indicators
Market Signals| Indicator | CMMB | TULP |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 22.83 |
| Support Level | $1.40 | $3.73 |
| Resistance Level | $1.64 | N/A |
| Average True Range (ATR) | 0.13 | 0.31 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 47.06 | 10.43 |
Price Performance
Historical Comparison CMMB
TULP
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.